How the fast Padé transform handles noise for MRS data from the ovary: importance for ovarian cancer diagnostics

详细信息    查看全文

• 作者：Dževad Belkić ; Karen Belkić
• 关键词：Magnetic resonance spectroscopy ; Ovarian cancer diagnostics ; Mathematical optimization ; Fast Padé transform
• 刊名：Journal of Mathematical Chemistry
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：54
• 期：1
• 页码：149-185
• 全文大小：1,115 KB
• 参考文献：1.M. Åkeson, A. Jakobsen, B. Zetterqvist, E. Holmberg, M. Brannström, G. Horvath, A population-based 5-year cohort study of epithelial ovarian cancer in western Sweden. Int. J. Gynecol. Cancer 19, 116–123 (2009)CrossRef
  2.V. Beral, Million Women Study Collaborators, ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369, 1703–1710 (2007)CrossRef
  3.P. Boyle, M.E. Leon, P. Maisonneuve, P. Autier, Cancer control in women. Update 2003. Int. J. Gynecol. Obstet. 83(Supplement 1), 179–202 (2003)CrossRef
  4.J. Schildkraut, A. Alberg, E. Bandera, J. Barnholtz-Sloan, M. Bondy, M. Cote, E. Funkhouser, E. Peters, A. Schwartz, P. Terry, K. Wallace, L. Akushevich, F. Wang, S. Crankshaw, P. Moorman, A multi-center population-based case–control study of ovarian cancer in African-American women: the African American Cancer Epidemiology Study (AACES). BMC Cancer 14, 688 (2014)CrossRef
  5.J. Menczer, I. Liphshitz, M. Barchana, A decreasing incidence of ovarian carcinoma in Israel. Int. J. Gynecol. Obstet. 16, 41–44 (2006)
  6.A. Ashworth, F. Balkwill, R.C. Bast, J.S. Berek, A. Kaye, J.A. Boyd, G. Mills, J.N. Weinstein, K. Woolley, P. Workman, Opportunities and challenges in ovarian cancer research, a perspective from the 11th ovarian cancer action/HHMT Forum, Lake Como, March 2007. Gynecol. Oncol. 108, 652–657 (2008)CrossRef
  7.M.A. Brewer, K. Johnson, M. Follen, D. Gershenson, R. Bast, Prevention of ovarian cancer: intraepithelial neoplasia. Clin. Cancer Res. 9, 20–30 (2003)
  8.N. Wentzensen, S. Wacholder, Talc use and ovarian cancer: epidemiology between a rock and a hard place. J. Natl. Cancer Inst. 106, dju260 (2014)CrossRef
  9.F. Salehi, L. Dunfield, K. Phillips, D. Krewski, B. Vanderhyden, Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J. Toxicol. Environ. Health 11, 301–321 (2008)CrossRef
  10.P.D.P. Pharoah, The potential for risk stratification in the management of ovarian cancer risk. Int. J. Gynecol. Cancer 22, S16–S17 (2012)CrossRef
  11.N. Wentzensen, B. Trabert, Hormone therapy: short-term relief, long-term consequences. Lancet (2015). doi:10.​1016/​S0140-6736(14)62458-2
  12.Å. Klint, L. Tryggvadottir, F. Bray, M. Gislum, T. Hakulinen, H. Storm, M. Enghol, Trends in the survival of patients diagnosed with cancer in female genital organs in Nordic countries. Acta Oncol. 49, 632–643 (2010)CrossRef
  13.P. Bhatti, K.L. Cushing-Haugen, K.G. Wicklund, J. Doherty, M.A. Rossing, Nightshift work and risk of ovarian cancer. Occup. Environ. Med. 70, 231–237 (2013)CrossRef
  14.S. Harlap, S.H. Olson, R.R. Barakat, T.A. Caputo, S. Forment, A.J. Jacobs, C. Nakraseive, X. Xue, Diagnostic X-rays and risk of epithelial ovarian carcinoma in Jews. Ann. Epidemiol. 12, 426–434 (2002)CrossRef
  15.E.R. Woodward, H.V. Sleightholme, A.M. Considine, S. Williamson, J.M. McHugo, D.G. Cruger, Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. Br J. Obstet. Gynaecol. 114, 1500–1509 (2007)CrossRef
  16.P. Mohaghegh, A.G. Rockall, Imaging strategy for early ovarian cancer: characterization of adnexal masses with conventional and advanced imaging techniques. Radiographics 32, 1751–1773 (2012)CrossRef
  17.S. Bhoola, W.J. Hoskins, Diagnosis and management of epithelial ovarian cancer. Obstet. Gynecol. 107, 1399–1410 (2006)CrossRef
  18.G. Chornokur, E. Armankwah, J. Schildkraut, C. Phelan, Global ovarian cancer health disparities. Gynecol. Oncol. 129, 258–264 (2013)CrossRef
  19.N. Einhorn, R. Bast, R. Knapp, B. Nilsson, V. Zurawski, K. Sjövall, Long-term follow-up of the Stockholm screening study on ovarian cancer. Gynecol. Oncol. 79, 466–470 (2000)CrossRef
  20.R.J. Kurman, K. Visvanathan, R. Roden, T.C. Wu, IeM Shih, Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am. J. Obstet. Gynecol. 198, 351–356 (2008)CrossRef
  21.M. Andersen, K. Lowe, B. Goff, Value of symptom-triggered diagnostic evaluation for ovarian cancer. Obstet. Gynecol. 123, 73–79 (2014)CrossRef
  22.U. Menon, M. Griffin, A. Gentry-Maharaj, Ovarian cancer screening—current status, future directions. Gynecol. Oncol. 132, 490–495 (2014)CrossRef
  23.H. Kobayashi, Y. Yamada, T. Sado, M. Sakata, S. Yoshida, S. Kawaguchi, S. Kanayama, H. Shigetomi, S. Haruta, Y. Tsuji, S. Ueda, T. Kitanaka, A randomized study of screening for ovarian cancer: a multi-center study in Japan. Int. J. Gynecol. Cancer 18, 414–420 (2008)CrossRef
  24.F. Kong, C. Nicole White, X. Xiao, Y. Feng, C. Xu, D. He, Z. Zhang, Y. Yu, Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer. Gynecol. Oncol. 100, 247–253 (2006)CrossRef
  25.I. Shapira, M. Oswald, J. Lovecchio, H. Khalili, A. Menzin, J. Whyte, L. Dos Santos, S. Liang, T. Bhuiya, M. Keogh, C. Mason, K. Sultan, D. Budman, P. Gregersen, A. Lee, Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br. J. Cancer 110, 976–983 (2014)CrossRef
  26.A.E. Lokshin, The quest for ovarian cancer screening biomarkers: are we on the right road? Int. J. Gynecol. Cancer 22, S35–S40 (2012)CrossRef
  27.V. Nossov, M. Amneus, F. Su, J. Lang, J.M. Janco, S.T. Reddy, R. Farias-Eisner, The early detection of ovarian cancer: from traditional methods to proteomics: can we really do better than serum CA-125? Am. J. Obstet. Gynecol. 199, 215–223 (2008)CrossRef
  28.K.L. Taylor, R. Shelby, E. Gelmann, C. McGuire, Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. J. Natl. Cancer Inst. 96, 1083–1094 (2004)CrossRef
  29.P.M. McGovern, C.R. Gross, R.A. Krueger, D.A. Engelhard, J.E. Cordes, T.R. Church, False-positive cancer screens and health-related quality of life. Cancer Nurs. 27, 347–352 (2004)CrossRef
  30.V.A. Moyer, Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation. Ann. Intern. Med. 157, 900–904 (2012)CrossRef
  31.A. Slomski, Screening women for ovarian cancer still does more harm than good. J. Am. Medical Assoc. 307, 2474–2475 (2012)
  32.R.J. Morgan, R.D. Alvarez, D.K. Armstrong, R.A. Burger, M. Castells, L.-M. Chen, L. Copeland, M.A. Crispens, D. Gershenson, H. Gray, A. Hakam, L.J. Havrilesky, C. Johnston, S. Lele, L. Martin, U.A. Matulonis, D.M. O’Malley, R.T. Penson, S.W. Remmenga, P. Sabbatini, J.T. Santoso, R.J. Schilder, J. Schink, N. Teng, T.L. Werner, M. Hughes, M.A. Dwyer, Ovarian cancer, version 3.2012. NCCN guidelines insights. J. Natl. Compr. Canc. Netw. 10, 1339–1349 (2012)
  33.K. Belkić, M. Cohen, M. Márquez, M. Mints, B. Wilczek, A.H. Berman, E. Castellanos, M. Castellanos, Screening of high-risk groups for breast and ovarian cancer in Europe: a focus on the Jewish population. Oncol. Rev. 4, 233–267 (2010)CrossRef
  34.I. Imaoka, T. Araki, M. Takeuchi, MRI of the female genitourinary tract, in Magnetic Resonance Volume 3 Comprehensive Biomedical Physics, ed. by Dž Belkić, K. Belkić (Elsevier, Amsterdam, 2014), pp. 221–240
  35.K. Kinkel, Y. Lu, A. Mehdizade, M.-F. Pelte, H. Hricak, Indeterminate ovarian mass at US. Radiology 236, 85–94 (2005)CrossRef
  36.S. Zhao, J. Qiang, G. Zhang, F. Ma, S. Cai, H. Li, L. Wang, Diffusion-weighted MR imaging for differentiating borderline from malignant epithelial tumours of the ovary: pathological correlation. Eur. Radiol. 24, 2292–2299 (2014)CrossRef
  37.D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011)CrossRef
  38.M.F. Kircher, H. Hricak, S.M. Larson, Molecular imaging for personalized cancer care. Mol. Oncol. 6, 182–195 (2012)CrossRef
  39.L.F.A.G. Massuger, P.B.J. van Vierzen, U. Engelke, A. Heerschap, R. Wevers, \(^{1}\) H magnetic resonance spectroscopy. A new technique to discriminate benign from malignant ovarian tumors. Cancer 82, 1726–1730 (1998)CrossRef
  40.S.J. Booth, M.D. Pickles, L.W. Turnbull, In vivo magnetic resonance spectroscopy of gynaecological tumors at 3.0 Tesla. Br. J. Obstet. Gynaecol. 116, 300–303 (2009)CrossRef
  41.S.W. Cho, S.G. Cho, J.H. Lee, H.-J. Kim, M.H. Lim, J.H. Kim, C.H. Suh, In vivo proton magnetic resonance spectroscopy in adnexal lesions. Korean J. Radiol. 3, 105–112 (2002)CrossRef
  42.A. Esseridou, G. Di Leo, L.M. Sconfienza, V. Caldiera, F. Raspagliesi, B. Grijuela, F. Hanozet, F. Podo, F. Sardanelli, In vivo detection of choline in ovarian tumors using 3D MRS. Invest. Radiol. 46, 377–382 (2011)CrossRef
  43.S. Hascalik, O. Celik, G. Erdem, Magnetic resonance spectral analysis of ovarian teratomas. Int. J. Gynecol. Obstet. 90, 152–152 (2005)CrossRef
  44.S. Hascalik, O. Celik, K. Sarak, M.M. Meydanli, A. Alkan, B. Mizrak, Metabolic changes in pelvic lesions: findings at proton MR spectroscopic imaging. Gynecol. Obstet. Invest. 60, 121–127 (2005)
  45.E. Kolwijck, U.F. Engelke, M. van der Graaf, A. Heerschap, J. Henk, H.J. Blom, M. Hadfoune, W.A. Buurman, L.F. Massuger, R.A. Wevers, N-acetyl resonances in in vivo and in vitro NMR spectroscopy of cystic ovarian tumors. NMR Biomed. 22, 1093–1099 (2009)
  46.M.A. McLean, A.N. Priest, I. Joubert, D.J. Lomas, M.Y. Kataoka, H. Earl, R. Crawford, J.D. Brenton, J.R. Griffiths, E. Sala, Metabolic characterization of primary and metastatic ovarian cancer by 1H-MRS in vivo at 3T. Magn. Reson. Med. 62, 855–861 (2009)CrossRef
  47.T. Okada, M. Harada, K. Matsuzaki, H. Nishitani, T.J. Aono, Evaluation of female intrapelvic tumors by clinical proton MR spectroscopy. Magn. Reson. Imaging 13, 912–917 (2001)CrossRef
  48.P. Stanwell, P. Russell, J. Carter, S. Pather, S. Heintze, C. Mountford, Evaluation of ovarian tumors by proton magnetic resonance spectroscopy at three Tesla. Invest. Radiol. 43, 745–751 (2008)CrossRef
  49.M. Takeuchi, K. Matsuzaki, M. Harada, Preliminary observations and diagnostic value of lipid peak in ovarian thecomas/fibrothecomas using in vivo proton MR spectroscopy at 3T. J. Magn. Reson. Imaging 36, 907–911 (2012)CrossRef
  50.E.A. Boss, S.H. Moolenaar, L.F. Massuger, H. Boonstra, U.F. Engelke, J.G. de Jong, R.A. Wevers, High-resolution proton nuclear magnetic resonance spectroscopy of ovarian cyst fluid. NMR Biomed. 13, 297–30 (2000)CrossRef
  51.J.C. Wallace, G.P. Raaphorst, R.L. Somorjai, C.E. Ng, M. Fung Kee Fung, M. Senterman, I.C. Smith, Classification of 1H MR spectra of biopsies from untreated and recurrent ovarian cancer using linear discriminant analysis. Magn. Reson. Med. 38, 569–576 (1997)CrossRef
  52.I.C. Smith, D.E. Blandford, Diagnosis of cancer in humans by 1H NMR of tissue biopsies. Biochem. Cell. Biol. 76, 472–476 (1998)CrossRef
  53.C.E. Mountford, S. Doran, C.L. Lean, P.L. Russell, Proton MRS can determine the pathology of human cancers with a high level of accuracy. Chem. Rev. 104, 3677–3704 (2004)CrossRef
  54.L. Gluch, Magnetic resonance in surgical oncology: II-literature review. ANZ. J. Surg. 75, 464–470 (2005)CrossRef
  55.J.K. Nicholson, I.D. Wilson, High resolution proton magnetic resonance spectroscopy of biological fluids. Prog. NMR Spectrosc. 21, 449–501 (1989)CrossRef
  56.Dž. Belkić, Strikingly stable convergence of the fast Padé transform (FPT) for high resolution parametric and non-parametric signal processing of Lorentzian and non-Lorentzian spectra. Nucl. Instrum. Methods Phys. Res. A 525, 366–371 (2004)
  57.Dž. Belkić, Quantum Mechanical Signal Processing and Spectral Analysis (Institute of Physics Publishing, Bristol, 2005)
  58.Dž. Belkić, K. Belkić, Signal Processing in Magnetic Resonance Spectroscopy with Biomedical Applications (Taylor & Francis, London, 2010)
  59.Dž. Belkić, Exact signal–noise separation by Froissart doublets in the fast Padé transform for magnetic resonance spectroscopy. Adv. Quantum Chem. 56, 95–179 (2009)
  60.Dž. Belkić, K. Belkić, The general concept of signal–noise separation (SNS). J. Math. Chem. 45, 563–597 (2009)
  61.K. Belkić, Resolution performance of the fast Padé transform: potential advantages for magnetic resonance spectroscopy in ovarian cancer diagnostics. Nucl. Instrum. Methods Phys. Res. A 580, 874–880 (2007)
  62.Dž. Belkić, K. Belkić, Mathematical modeling applied to an NMR problem in ovarian cancer detection. J. Math. Chem. 43, 395–425 (2008)
  63.Dž. Belkić, K. Belkić, Magnetic resonance spectroscopy with high-resolution and exact quantification in the presence of noise for improving ovarian cancer detection. J. Math. Chem. 50, 2558–2576 (2012)
  64.Dž. Belkić, K. Belkić, Resolution enhancement as a key step towards clinical implementation of Padé-optimized magnetic resonance spectroscopy for diagnostic oncology. J. Math. Chem. 51, 2608–2637 (2013)
  65.Dž. Belkić, K. Belkić, Strategic steps for advanced molecular imaging with magnetic resonance-based diagnostic modalities. Technol. Cancer Res. Treat. 14, 119–142 (2015)
  66.A.C. Ojo, The Analysis and Automatic Classification of Nuclear Magnetic Resonance Signals. PhD Thesis. (The University of Edinburgh, 2010), Edinburgh Research Archive, http://​hdl.​handle.​net/​1842/​4109
  67.Dž. Belkić, Analytical continuation by numerical means in spectral analysis using the fast Padé transform (FPT). Nucl. Instrum. Methods Phys. Res. A 525, 372–378 (2004)
  68.Dž. Belkić, Exact quantification of time signals in Padé-based magnetic resonance spectroscopy. Phys. Med. Biol. 51, 2633–2670 (2006)
  69.K. Glunde, J. Jiang, S.A. Moestue, I.S. Gribbestad, MRS/MRSI guidance in molecular medicine: targeting choline and glucose metabolism. NMR Biomed. 24, 673–690 (2011)CrossRef
  70.Dž. Belkić, K. Belkić, Proof-of-the-concept study on mathematically optimized magnetic resonance spectroscopy for breast cancer diagnostics. Technol. Cancer Res. Treat. (2014). doi:10.​1177/​1533034614547446​
  71.Dž. Belkić, K. Belkić, Padé optimization of noise-corrupted magnetic resonance spectroscopic time signals from fibroadenoma of the breast. J. Math. Chem. 52, 2680–2713 (2014)
  72.Dž. Belkić, K. Belkić, Optimized spectral analysis in magnetic resonance spectroscopy for early tumor diagnostics. J. Phys. Conf. Ser. 565, 012002 (2014). doi:10.​1088/​1742-6596/​565/​1/​012002
  73.E. Iorio, D. Mezzanzanica, P. Alberti, F. Spadaro, C. Ramoni, S. D’Ascenzo, D. Millimaggi, A. Pavan, V. Dolo, S. Canavari, F. Podo, Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 65, 9369–9376 (2005)CrossRef
  74.Dž. Belkić, K. Belkić, Molecular imaging in the framework of personalized cancer medicine. Isr. Med. Assoc. J. 15, 665–672 (2013)
  75.Dž. Belkić, K. Belkić, The role of optimized molecular imaging in personalized cancer medicine. Diag. Imaging Eur. 30, 28–31 (2014)
  76.M. Mescher, H. Merkle, J. Kirsch, M. Garwood, R. Gruetter, Simultaneous in vivo spectral editing and water suppression. NMR Biomed. 11, 266–272 (1998)CrossRef
  77.P.A. Bottomley, The trouble with spectroscopy papers. J. Magn. Reson. Imaging 2, 1–8 (1992)CrossRef
  
• 作者单位：Dževad Belkić (1)
  Karen Belkić (1) (2) (3)
  
  1. Department of Oncology-Pathology, Karolinska Institute, Building P-9, 2nd Floor, P.O. Box 260, 17176, Stockholm, Sweden
  2. School of Community and Global Health, Claremont Graduate University, Claremont, CA, USA
  3. Institute for Prevention Research, Keck School of Medicine, University of Southern California, Alhambra, CA, USA
  
• 刊物类别：Chemistry and Materials Science
• 刊物主题：Chemistry
  Physical Chemistry
  Theoretical and Computational Chemistry
  Mathematical Applications in Chemistry
  
• 出版者：Springer Netherlands
• ISSN：1572-8897

文摘

Advanced signal processing through the fast Padé transform (FPT) can enhance resolution and generates quantitative metabolic information for magnetic resonance spectroscopy (MRS). Herein, we apply both \(\hbox {FPT}^{(\pm )}\) variants to in vitro MRS data as encoded from benign and malignant ovarian cyst fluid and perform detailed analysis with several noise levels. In the presence of higher background noise, all genuine metabolites were unambiguously identified and their concentrations precisely computed, using small fractions of the total signal length by both FPT variants. In the \(\hbox {FPT}^{(-)}\), signal–noise separation was accomplished with the help of the “Stability test”, whereby the non-physical information is binned and denoised spectra are generated. In the \(\hbox {FPT}^{(+)}\) even more stringent signal–noise separation was achieved: the spurious resonances reside exclusively in the negative imaginary frequency domain, whereas the genuine content is all in the positive imaginary frequency region. Pole-zero coincidence of spurious resonance remained complete in the \(\hbox {FPT}^{(+)}\) even at higher noise levels. Via the \(\hbox {FPT}^{(+)}\), a denoised spectrum is generated automatically, without the need for the “Stability test”. The two variants \(\hbox {FPT}^{(\pm )}\) provide self-contained cross-validation of the reconstructed spectral parameters, from which the metabolite concentrations of benign and malignant ovarian cyst fluid are reliably computed. These results are particularly promising for more effective ovarian cancer diagnostics, overcoming the major obstacles that have hindered MRS from becoming the method of choice for non-invasive assessment of ovarian lesions. Keywords Magnetic resonance spectroscopy Ovarian cancer diagnostics Mathematical optimization Fast Padé transform